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Abstract
Background: The prognostic benefits of beta-blockers (BB) in patients with systolic heart failure (SHF) are known
but despite this, in patients with diabetes they are underutilized. The aim of this study was to assess the effect of
beta-blockers (BB) on glycaemic control in patients with Type 2 Diabetes (T2DM) and systolic heart failure (SHF)
stratified to beta-1 selective (Bisoprolol) vs. nonselective BB (Carvedilol).
Methods: This observational, cohort study was conducted in patients with T2DM and SHF attending an Australian
tertiary teaching hospital’s heart failure services. The primary endpoint was glycaemic control measured by
glycosylated haemoglobin (HbA1c) at initiation and top dose of BB. Secondary endpoints included
microalbuminuria, changes in lipid profile and estimated glomerular filtration rate (eGFR).
Results: 125 patients were assessed. Both groups were well matched for gender, NYHA class and use of guideline
validated heart failure and diabetic medications. The mean treatment duration was 1.9 ± 1.1 years with carvedilol
and 1.4 ± 1.0 years with bisoprolol (p = ns). The carvedilol group achieved a reduction in HbA1c (7.8 ± 0.21% to
7.3 ± 0.17%, p = 0.02) whereas the bisoprolol group showed no change in HbA1c (7.0 ± 0.20% to 6.9 ± 0.23%, p =
0.92). There was no significant difference in the change in HbA1c from baseline to peak BB dose in the carvedilol
group compared to the bisoprolol group. There was a similar deterioration in eGFR, but no significant changes in
lipid profile or microalbuminuria in both groups (p = ns).
Conclusion: BB use did not worsen glycaemic control, lipid profile or albuminuria status in subjects with SHF and
T2DM. Carvedilol significantly improved glycemic control in subjects with SHF and T2DM and this improvement
was non significantly better than that obtained with bisoprolol. BB’s should not be withheld from patients with
T2DM and SHF.
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Background
The prognostic benefits of beta-blockers (BB) in patients
with systolic heart failure (SHF) are known [1,2] but
despite this, patients with diabetes have been identified
as receiving suboptimal treatment with BB [3,4]. The
prevalence of SHF in patients with T2DM is ~ 12%
whilst in patients with left ventricular systolic dysfunc-
tion 6-25% have T2DM [5]. It would seem clear that in
the management of patients with both T2DM and SHF,
use of beta-blockers whilst maintaining good glycaemic
control is paramount to improved clinical outcomes
[6-8]. In hypertensive subjects with T2DM without SHF,
carvedilol has been shown to have favorable effects on
glycaemic control in comparison with metoprolol tar-
trate [9].
We aimed to assess the glycaemic control of patients
with T2DM and SHF treated with BB in a tertiary teach-
ing hospital and the differential effects of a nonselective
BB (carvedilol) versus a b1 selective BB (bisoprolol) on
glycaemic control, renal function, albuminuria and lipid
profile.
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Patients
Consecutive patients that were referred following an
index hospitalization with decompensated SHF and
T2DM to our multidisciplinary heart failure clinic were
enrolled. Patients were followed up prospectively.
Heart failure management
Patients received either carvedilol or bisoprolol and the
doses were titrated to a maximal tolerated dose (target
of 10 mg of bisoprolol or 50 mg of carvedilol per day).
The choice of beta-blocker was left to the discretion of
the treating cardiologist, with other heart failure man-
agement utilization as per accepted guidelines [2].
Patients included were not on beta-blockers prior to
index hospitalization.
Diabetes management
Patients were managed for their diabetes by their pri-
mary care and specialist diabetes physician. The number
of anti-diabetic medications in both groups during the
follow-up period did not change.
Measured variables
SHF was defined as presence of symptoms and signs of
heart failure and left ventricular ejection fraction less than
50%. New York Heart Association Class (NYHA) was
recorded at the first outpatient visit along with collection
of serum and urine samples at commencement and within
3 months of achieving peak tolerated dose of BB. Glycae-
mic control was assessed by glycosylated haemoglobin
(HbA1c) which is measured by automated HPLC (Bio-Rad
Laboratories, California, USA). Renal function by esti-
mated Glomerular Filtration Rate (eGFR) and albuminuria
by using the ratio of urinary albumin concentration to
urinary creatinine concentration (ACR). Microalbuminuria
was defined as ACR greater than 30 mg/g and less than
300 mg/g. To assess changes in lipid profile, fasting total
cholesterol (TC), high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) and triglyceride (TG) level were
measured according to previously published methods [10].
Statistical analysis
Continuous data are presented as mean ± standard
deviation and categorical data as n (%). Changes in
HbA1c, eGFR, microalbuminuria and lipid profile were
examined using t-tests. Categorical variables were com-
pared using Fisher’s exact test. Statistical significance
was taken as p < 0.05.
Results
Data from a total of 125 patients with SHF and T2DM
was analyzed (n = 80 carvedilol, n = 45 bisoprolol). The
mean treatment duration from baseline to peak BB dose
was 1.9 ± 1.1 years with carvedilol and 1.4 ± 1.0 years
with bisoprolol (p = ns). The mean peak dose of carve-
dilol was 26.5 ± 21.1 mg/day and bisoprolol was 5.8 ±
3.0 mg/day. Both groups were well matched for gender
(majority male), NYHA class, and use of guideline vali-
dated therapies i.e. renin angiotensin system inhibitors,
diuretics, spironolactone and diabetes treatment (diet,
oral hypoglycaemics and/or insulin). (Table 1)
For the primary endpoint, glycaemic control improved
in the carvedilol group but no significant change was
noted in the bisoprolol group (Table 2). No significant
difference was seen between the changes in HbA1c in
the carvedilol group vs. bisoprolol group (-0.5 ± 1.4% vs.
0.2 ± 1.3%; p = 0.09) (Figure 1). Both groups had signifi-
cant reductions in eGFR from baseline to peak BB dose,
b u tw i t hn os i g n i f i c a n td i f f e r e n c ei nt h i sr e d u c t i o n
between the carvedilol and bisoprolol groups. The pro-
portion of patients with microalbuminuria remained the
same in both groups for the duration of the study.
There were no significant differences in the lipid profile
between the two groups for the duration of the study.
Discussion
The major finding of this study is that BB use did not
worsen glycaemic control, lipid profile nor albuminuria
status in patients with T2DM and SHF, suggesting that
these medications should not be withheld in this high-
risk group. This is in contradiction to the GEMINI
study, where hypertensive T2DM patients randomized
to carvedilol (nonselective BB) did not have a significant
Table 1 Patient’s baseline characteristics
Carvedilol
(n = 80)
Bisoprolol
(n = 45)
p-value
Demographics
Male 62 (78%) 34 (76%) 0.83
Age (years) 71.0 ± 9.7 70.7 ± 10.8 0.89
NYHA (mean) 2.1 ± 0.7 2.1 ± 0.6 0.90
NYHA Class I 14 (18%) 5 (11%)
NYHA Class II 45 (56%) 30 (67%)
NYHA Class III 18 (22%) 10 (22%)
NYHA Class IV 3 (4%) 0
Diabetic Medications
Diet 12 (15%) 5 (11%) 0.60
Oral hypoglycaemic 49 (61%) 27 (60%) 1.00
Insulin 19 (24%) 13 (29%) 0.53
Heart Failure Medications
ACEI 61 (76%) 33 (73%) 0.83
ARB 24 (30%) 14 (31%) 1.00
ACE I and ARB 9 (11%) 4 (9%) 0.77
Spironolactone 50 (62%) 26 (58%) 0.70
Thiazide 11 (14%) 9 (20%) 0.45
ACEI = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin Receptor
Blocker
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trate (selective b1B B )h a das i g n i f i c a n ti n c r e a s ei n
HbA1c [9]. Futhermore, in a sub-analysis of the
GEMINI study an increase in insulin resistance as mea-
sured by homeostasis model assessment-insulin resis-
tance (HOMA-IR) was found in patients treated with
metoprolol compared to carvedilol[11]. In another
study, metoprolol use in patients with type 2 diabetes
mellitus was shown to be associated with a significant
r e d u c t i o ni ni n s u l i n - s t i m u lated endothelial function
where as this function was preserved with carvedilol use
[12] One proposed mechanism for this was that selective
b1B B ’s such as atenolol and metoprolol may cause
vasoconstriction, decreased peripheral blood flow and
may exacerbate insulin resistance [13], whereas the a-
adrenergic blocking effect of carvedilol may allow
greater peripheral blood flow and hence increased utili-
zation of glucose. . This differential effect on glycaemic
control seen in hypertensive diabetics may not be
applicable to patients with systolic heart failure due to
their overactive sympathetic tone. In addition we found
that there was a significant improvement in glycaemic
control between baseline to peak BB dose within the
carvedilol group but not within the bisoprolol group.
Whilst there was also a strong trend for better glycae-
mic control in the carvedilol group compared to the
bisoprolol group, this did not quite reach statistical sig-
nificance. This result could possibly have been biased by
different baseline HbA1c levels between the two groups
and therefore does not provide absolute evidence for the
differential effects on glycaemic control between carve-
dilol and bisoprolol.
The GEMINI study also showed that patients on car-
vedilol had a greater reduction in microalbuminuria
when compared to patients taking metoprolol [14]. Such
differences were not seen in our study. This could be
Table 2 Glycaemic control, lipid profile and renal function in both groups at baseline and at peak beta-blocker dose
Carvedilol Bisoprolol
Baseline Peak BB p-value Baseline Peak BB p-value
Glycaemic control
HbA1c 7.7 ± 1.5 7.2 ± 1.2 0.02 7.0 ± 1.2 6.9 ± 1.3 0.92
Lipid Profile
TC/HDL 4.1 ± 1.0 3.7 ± 1.1 0.07 3.1 ± 1.0 3.0 ± 1.2 0.67
LDL/HDL 2.2 ± 0.9 2.0 ± 0.9 0.08 1.5 ± 0.7 1.5 ± 1.0 0.83
TG 1.9 ± 1.2 2.0 ± 1.5 0.66 1.6 ± 1.2 1.5 ± 0.9 0.52
Renal function
eGFR 53.6 ± 27.8 48.4 ± 27.4 0.01 60.4 ± 24.2 51.1 ± 26.9 < 0.01
ACR 0.7 ± 0.8 0.6 ± 0.72 0.6 0.9 ± 0.9 0.7 ± 1.0 1.00
Figure 1 Mean HbA1c ± standard deviation at baseline and at peak beta-blocker dose.
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dence of microalbuminuria in patients with SHF [15].
Half of the patients in our study had microalbuminuria
for the duration of the study, which is a higher propor-
tion than found in the general population of patients
with T2DM. The National Health and Nutrition Exami-
nation Survey found microalbuminuria in 29% of
patients with diabetes mellitus [16] whereas the PRE-
VEND study noted only 16% of patients with diabetes
mellitus had microalbuminuria [17]. The higher inci-
d e n c eo fm i c r o a l b u m i n u r i ai no u rs t u d yi sl i k e l yt ob e
mediated via impairment of endothelial function[15,18].
A recent study by Jawa et al. in African American sub-
jects with T2DM and hypertension suggested that there
was an improvement in endothelial function and albu-
minuria with commencement of carvedilol but without
significant change in albuminuria with metoprolol [19].
In contrast, a recent study in in patients with mild heart
failure (16% diabetic) failed to show a change in
endothelium-dependent vasodilatation when the beta-
blocker was changed from carvedilol to metoprolol suc-
cinate or tartrate [20]. We did not find any significant
changes in albuminuria over the follow-up period in
either group.
A concern of treating physicians has often been that
BB use would lead to elevation of triglycerides and low-
ering of HDL. A study by Pollare et al. demonstrated
significant elevation in LDL to HDL ratio and triglycer-
ide levels with the use of metoprolol or atenolol [21]. In
a more contemporary cohort, beta-blocker use was not
associated with a deterioration in lipid profile but sug-
gest greater statin use with metoprolol when compared
to carvedilol[22]. In our study, no worsening in lipid
profiles was seen in either group of patients whilst on
BB. This might be related to a greater use of statins
amongst our cohort of patients.
Traditional teaching for T2DM has been that BB may
worsen hypoglycaemic awareness, glycaemic control and
lipid metabolism and should be used with caution. How-
ever, the prognosis of patients that develop SHF is poor
and is markedly improved by appropriate BB therapy.
Although the use of beta-blockers in T2DM and SHF
has not been specifically studied, meta-analyses of large-
scale clinical trials have demonstrated the prognostic
benefit of beta-blockers in SHF patients who also have
diabetes mellitus [23]. Indeed to the authors knowledge
there is only one other study that has compared carvedi-
lol to bisoprolol in patients with SHF where, retrospec-
tively after 18 months of follow up, no significant
differences were found in survival or cardiac morbidity
[24] In addition, strict glycaemic control is essential to
the management of patients with diabetes mellitus. In
the United Kingdom Prospective Diabetic Study, lower-
ing of HbA1c toward 6% resulted in significant
reductions of micro vascular and macro vascular com-
plications and death related to T2DM, including SHF
[8]. Furthermore, poor glycaemic control is associated
with increased incidence of heart failure, hospitalization
and death [7]. It is clear that in the management of
patients with T2DM and SHF, the use of beta-blockers
whilst maintaining good glycaemic control is important.
Limitations
This study was an observational cohort study and not a
randomised control trial. Hence the choice of beta blocker
and diabetic therapies were left to the treating cardiologist
and endocrinologist and thus could be a possible source of
bias. Despite this, both cohorts were well matched at base-
line for diabetes and heart failure treatment. Nevertheless,
because the initial HbA1c readings were different between
the two groups, it is difficult to draw an absolute conclu-
sion regarding the differential effects of carvedilol and
metoprolol. (selective vs. nonselective)
Conclusion
In conclusion, BB use did not worsen glycaemic control,
lipid profile nor albuminuria status in patients with
T2DM and SHF, suggesting that these medications
should not be withheld in this group of patients. Carve-
dilol significantly improved glycemic control in patients
with T2DM and SHF and that this improvement was
non significantly better than that obtained with
bisoprolol.
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